Update on the clinical pharmacogenomics of organ transplantation

Pharmacogenomics

Volumn 11, Issue 2, 2010, Pages 227-236

  Burckart, Gilbert J ^a   Amur, Shashi ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NONE

Author keywords

Biomarker; CYP3A5; Drug development; Gene expression array; Organ transplantation; P glycoprotein; Pharmacogenomics

Indexed keywords

BETA 2 MICROGLOBULIN; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOKINE; GLYCOPROTEIN P; GLYCOSYLTRANSFERASE; GROWTH FACTOR; INOSINATE DEHYDROGENASE; INOSINE 5' MONOPHOSPHATE DEHYDROGENASE 1; INOSINE 5' MONOPHOSPHATE DEHYDROGENASE 2; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; URIDINE GLYCOSYLTRANSFERASE;

ACUTE GRAFT REJECTION; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PATIENT CARE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENOMICS; PROTEINURIA; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; BIOLOGICAL MARKERS; CYTOCHROME P-450 CYP3A; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; GLUCURONOSYLTRANSFERASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; ORGAN TRANSPLANTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 77949587568     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.177     Document Type: Review

References (73)

1. Burckart GJ: Pharmacogenomics: the key to improved drug therapy in transplant patients. Clin. Lab. Med. 28(3), 411-422 (2008).
2. Macphee IAM, Fredericks S, Tai T et al.: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74(11), 1486-1489 (2002).
3. Zheng HX, Webber S, Schuetz E et al.: Cytochrome P4503A5 and TNF-a genotypes are associated with tacrolimus dosing in pediatric heart transplant patients. Hum. Immunol. 63(Suppl. 1), S15 (2002).
4. Zheng H, Zeevi A, Schuetz E et al.: Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol. 44(2), 135-140 (2004).
5. Goto M, Masuda S, Kiuchi T et al.: CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14(7), 471-478 (2004).
6. Yu S, Wu L, Jin J et al.: Infuence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 81(1), 46-51 (2006).
7. MacPhee IA, Fredericks S, Tai T et al.: The infuence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. 4(6), 914-919 (2004).
8. Thervet E, Loriot MA, Barbier S et al.: Prospective randomized study of pharmacogenetic adaptation of tacrolimus treatment after renal transplantation. Transplantation 86(Suppl. 2), 185 (2008).
9. Kuypers DR, de Jonge H, Naesens M et al.: CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin. Pharmacol. Ther. 82(6), 711-725 (2007).
10. Klauke B, Wirth A, Zittermann A et al.: No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. J. Heart Lung Transplant. 27(7), 741-745 (2008).
11. Chen JS, Li LS, Cheng DR et al.: Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. Transplant. Proc. 41(5), 1557-1561 (2009).
12. Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V: Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol. Dial. Transplant. 22(7), 1963-1968 (2007).
13. Fukudo M, Yano I, Yoshimura A et al.: Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet. Genomics 18(5), 413-423 (2008).
14. Ferraresso M, Tirelli A, Ghio L et al.: Infuence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr. Transplant. 11(3), 296-300 (2007).
15. Burckart GJ: Looking beneath the surface of the CYP3A5 polymorphism. Pediatr. Transplant. 11(3), 239-240 (2007).
16. Bochud M, Bovet P, Burnier M, Eap CB: CYP3A5 and ABCB1 genes and hypertension. Pharmacogenomics 10(3), 477-487 (2009).
17. Le Meur Y, Djebli N, Szelag JC et al.: CYP3A5*3 infuences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin. Pharmacol. Ther. 80(1), 51-60 (2006).
18. Lee SJ, Jusko WJ, Salaita CG et al.: Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition. J. Clin. Pharmacol. 46(5), 515-526 (2006).
19. Miura M, Satoh S, Inoue K et al.: Infuence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids 73(11), 1052-1059 (2008).
20. Zhang B, Xie W, Krasowski MD: PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9, 1695-1709 (2008).
21. Kreutz R, Bolbrinker J, van der Sman-de Beer F et al.: CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine. Pharmacogenomics J. 8(6), 416-422 (2008).
22. Kimchi-Sarfaty C, Oh JM, Kim IW et al.: A 'silent' polymorphism in the MDR1 gene changes substrate specifcity. Science 315(5811), 525-528 (2007).
23. Zheng HX, Webber SA, Zeevi A et al.: The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression ana lysis. Pediatr. Transplant. 8(6), 551-557 (2004).
24. Wang J, Figurski M, Shaw LM, Burckart GJ: The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. Transpl. Immunol. 19(3-4), 192-196 (2008).
25. Wang J, Zeevi A, McCurry K et al.: Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors. Transpl. Immunol. 15(3), 235-240 (2006).
26. Crettol S, Venetz JP, Fontana M et al.: Infuence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet. Genomics 18(4), 307-315 (2008).
27. Hauser IA, Schaeffeler E, Gauer S et al.: ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol. 16(5), 1501-1511 (2005).
28. Hawwa AF, McKiernan PJ, Shields M, Millership JS, Collier PS, McElnay JC: Infuence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br. J. Clin. Pharmacol. 68(3), 413-421 (2009).
29. Yamauchi A, Ieiri I, Kataoka Y et al.: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74(4), 571-572 (2002).
30. Asano T, Takahashi KA, Fujioka M et al.: ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 13(11), 675-682 (2003).
31. De Iudicibus S, Castronovo G, Gigante A et al.: Role of MDR1 gene polymorphisms in gingival overgrowth induced by cyclosporine in transplant patients. J. Periodont. Res. 43(6), 665-672 (2008).
32. Zheng HX, Zeevi A, McCurry K et al.: The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl. Immunol. 14(1), 37-42 (2005).
33. Barnard JB, Richardson S, Sheldon S et al.: The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection. Transplantation 82(12), 1677-1682 (2006).
34. Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, Viklicky O: Haplotypic structure of ABCB1/MDR1 gene modifes the risk of the acute allograft rejection in renal transplant recipients. Transplantation 86(9), 1206-1213 (2008).
35. Grinyo J, Vanrenterghem Y, Nashan B et al.: Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl. Int. 21(9), 879-891 (2008).
36. Cattaneo D, Ruggenenti P, Baldelli S et al.: ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J. Am. Soc. Nephrol. 20(6), 1404-1415 (2009).
37. van Gelder T, Shaw LM: The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 80(Suppl. 2), S244-253 (2005).
38. de Jonge H, Naesens M, Kuypers DR: New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther. Drug Monit. 31(4), 416-435 (2009).
39. Miura M, Satoh S, Inoue K et al.: Infuence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63(12), 1161-1169 (2007).
40. van Schaik RH, van Agteren M, de Fijter JW et al.: UGT1A9-275T>A/- 2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/ tacrolimus-treated kidney transplant patients. Clin. Pharmacol. Ther. 86(3), 319-327 (2009).
41. Bremer S, Mandla R, Vethe NT et al.: Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation 85(1), 55-61 (2008).
42. Wang J, Yang JW, Zeevi A et al.: IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin. Pharmacol. Ther. 83(5), 711-717 (2008).
43. Bowne SJ, Sullivan LS, Blanton SH et al.: Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum. Mol. Genet. 11(5), 559-568 (2002).
44. Sombogaard F, van Schaik RH, Mathot RA et al.: Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet. Genomics 19(8), 626-634 (2009).
45. Wang J, Zeevi A, Webber S et al.: A novel variant L263F in human inosine 5́-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet. Genomics 17(4), 283-290 (2007).
46. Girnita DM, Brooks MM, Webber SA et al.: Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi-institutional study. Transplantation 85(11), 1632-1639 (2008).
47. Brabcova I, Petrasek J, Hribova P et al.: Genetic variability of major infammatory mediators has no impact on the outcome of kidney transplantation. Transplantation 84(8), 1037-1044 (2007).
48. Weintraub LA, Sarwal MM: Microarrays: a monitoring tool for transplant patients? Transpl. Int. 19(10), 775-788 (2006).
49. Hoffmann SC, Kampen RL, Amur S et al.: Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation 74(7), 916-923 (2002).
50. Perco P, Pleban C, Kainz A, Lukas A, Mayer B, Oberbauer R: Gene expression and biomarkers in renal transplant ischemia reperfusion injury. Transpl. Int. 20(1), 2-11 (2007).
51. Hoffmann SC, Hale DA, Kleiner DE et al.: Functionally signifcant renal allograft rejection is defned by transcriptional criteria. Am. J. Transplant. 5(3), 573-581 (2005).
52. Lande JD, Patil J, Li N, Berryman TR, King RA, Hertz MI: Novel insights into lung transplant rejection by microarray ana lysis. Proc. Am. Thorac. Soc. 4(1), 44-51 (2007).
53. Sarwal MM, Li L: Designer genes: flling the gap in transplantation. Transplantation 82(10), 1261-1272 (2006).
54. Kurian S, Grigoryev Y, Head S, Campbell D, Mondala T, Salomon DR: Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers. Int. Immunopharmacol. 7(14), 1948-1960 (2007).
55. Braud C, Baeten D, Giral M et al.: Immunosuppressive drug-free operational immune tolerance in human kidneytransplant recipients: Part I. Blood gene expression statistical ana lysis. J. Cell. Biochem. 103(6), 1681-1692 (2008).
56. Sarwal MM: Chipping into the human genome: novel insights for transplantation. Immunol. Rev. 210, 138-155 (2006).
57. Glas AM, Floore A, Delahaye LJ et al.: Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7, 278 (2006).
58. Fang KC: Clinical utilities of peripheral blood gene expression profling in the management of cardiac transplant patients. J. Immunotoxicol. 4, 209-217 (2007).
59. Deng MC, Eisen HJ, Mehra MR et al.: Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profling. Am. J. Transplant. 6(1), 150-160 (2006).
60. Mehra MR, Kobashigawa JA, Deng MC et al.: Transcriptional signals of T-cell and corticosteroid-sensitive genes are associated with future acute cellular rejection in cardiac allografts. J. Heart Lung Transplant. 26(12), 1255-1263 (2007).
61. Desai M, Stockbridge N, Temple R: Blood pressure as an example of a biomarker that functions as a surrogate. AAPS J. 8(1), E146-E152 (2006).
62. Burckart GJ, Amur S, Goodsaid FM et al.: Qualifcation of biomarkers for drug development in organ transplantation. Am. J. Transplant. 8(2), 267-270 (2008).
63. Sigdel TK, Sarwal MM: The proteogenomic path towards biomarker discovery. Pediatr. Transplant. 12(7), 737-747 (2008).
64. Khatri P, Sarwal MM: Using gene arrays in diagnosis of rejection. Curr. Opin. Organ Transplant. 14(1), 34-39 (2009).
65. Yamani MH, Taylor DO, Haire C, Smedira N, Starling RC: Post-transplant ischemic injury is associated with up-regulated AlloMap gene expression. Clin. Transplant. 21(4), 523-525 (2007).
66. Mehra MR, Kobashigawa JA, Deng MC et al.: Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection. J. Heart Lung Transplant. 27(3), 297-301 (2008).
67. Yamani MH, Taylor DO, Rodriguez ER et al.: Transplant vasculopathy is associated with increased AlloMap gene expression score. J. Heart Lung Transplant. 26(4), 403-406 (2007).
68. Goodsaid F, Frueh F: Biomarker qualifcation pilot process at the US Food and Drug Administration. AAPS J. 9(1), E105-E108 (2007).
69. Hinman L, Spear B, Tsuchihashi Z et al.: Drug-diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/ DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop. Pharmacogenomics 10(1), 127-136 (2009).
70. Goldfarb-Rumyantzev AS, Naiman N: Genetic prediction of renal transplant outcome. Curr. Opin. Nephrol. Hypertens. 17(6), 573-579 (2008).
71. Burckart GJ, Frueh FW, Lesko LJ: Progress in the direct application of pharmacogenomics to patient care: sustaining innovation. J. Appl. Pharmacol. 15, 1-6 (2007).
72. Burckart GJ, Liu XI: Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics? Ther. Drug Monit. 28(1), 23-30 (2006).
73. Bai JPF, Lesko LJ, Burckart GJ: Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors. Pharmacotherapy 30(2), 195-209 (2010).